{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-256533","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.932736+00:00","generated_at":"2026-06-09T23:25:14.640852+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxcyte subsidiary signs commercial manufacturing deal with Lonza for pneumococcal vaccine","bullets":["Lonza will build a dedicated suite in Visp, Switzerland to manufacture drug substance for Vaxcyte's pneumococcal conjugate vaccine franchise.","Vaxcyte GmbH pays CHF 27M repurposing fee within 30 days, credited over 10 years from commercial production start.","Agreement term through Dec 31, 2038, renewable for three 5-year periods; termination penalty up to CHF 70M under certain conditions.","Vaxcyte retains right to use alternate manufacturers; receives perpetual, royalty-free license to Lonza's IP for the Products.","Pre-commercial service fees and capital expenditure contributions commence before suite certification for commercial operation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-256533","json":"https://secwatch.observer/filing/0001193125-23-256533.json","markdown":"https://secwatch.observer/filing/0001193125-23-256533.md","text":"https://secwatch.observer/filing/0001193125-23-256533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/0001193125-23-256533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/d572225d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:25:14.640852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43ddf85014b06dc66258ab1c0cc62c7c6df9a34a","claim":"Vaxcyte, Inc. entered into Commercial Manufacturing and Supply Agreement with Lonza Ltd (effective 2023-10-13).","evidence_excerpt":"On October 13, 2023 (the “Effective Date”), Vaxcyte Switzerland GmbH (“Vaxcyte GmbH”), a Swiss limited liability company that, as of such date, was in the process of being formed by Vaxcyte, Inc. (“Vaxcyte”) (as a wholly-owned subsidiary of Vaxcyte), entered into a pre-commercial services and commercial manufacturing supply agreement (the “Commercial Manufacturing and Supply Agreement”) with Lonza Ltd (“Lonza”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523256533/0001193125-23-256533-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Lonza Ltd"},{"label":"Effective","value":"2023-10-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}